THE ANTIPHOSPHOLIPID SYNDROME AND THE LUPUS ANTICOAGULANT

被引:24
作者
CAMERON, JS
FRAMPTON, G
机构
[1] Renal Unit, Clinical Science Laboratories, Guy's Hospital, London, SE1 9RT
关键词
ANTIPHOSPHOLIPID ANTIBODIES; LUPUS ANTICOAGULANT; RECURRENT THROMBOSIS; THROMBOCYTOPENIA; FETAL LOSS; GLOMERULAR THROMBI;
D O I
10.1007/BF00858647
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
In recent years an association has been described between, on the one hand, an in vitro prolongation of phospholipid-dependent coagulation tests (the 'lupus anti-coagulant') or the demonstration of antiphospholipid antibodies and, on the other, clinical events, particularly recurrent thrombosis (usually venous but sometimes arterial), thrombocytopenia, and also recurrent mid-term fetal loss. Other less well-documented associations with haemolytic anaemia, livedo reticularis, strokes and other neurological syndromes have been suggested. The antibodies are present temporarily in many infections, are usually of IgM isotype and thrombosis does not occur. However, they are persistently present and mainly of IgG isotype in a number of auto-immune disorders associated with thrombosis, in particular systemic lupus erythematosus, in which 50% of patients will show antibody of one isotype or another. The strongest association is with antinuclear factor-negative lupus and 'lupus-like' disorders in which a full diagnosis of classical lupus cannot be made. The clotting test abnormality and antiphospholipid antibodies may be found also in otherwise normal individuals suffering thrombosis or fetal loss - the so-called primary antiphospholipid syndrome. These data raise important questions for management, but many details are controversial despite a decade's work; this review examines the present position and outlines some of the difficulties, particularly from the point of view of nephrology and paediatrics.
引用
收藏
页码:663 / 678
页数:16
相关论文
共 176 条
[1]  
Wasserman A., Neisser A., Bruck C., Eine serologische Reaktion bei Syphilis, Dtsch Med Wochenschr, 32, pp. 745-746, (1906)
[2]  
Pangborn M.C., A new serologically active phospholipid from beef heart, Experimental Biology and Medicine, 48, pp. 484-486, (1941)
[3]  
Gennerich W., Über die Ätiologie des lupus erythematodes, Arch Syphil Dermatol, 135, pp. 184-207, (1921)
[4]  
Moore J.E., Lutz W.B., The natural history of lupus erythematosus: an approach to its study through chronic biologic false positive reactors, J Chron Dis, 1, pp. 297-316, (1955)
[5]  
Conley C.C., Hartmann R.C., A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus, J Clin Invest, 31, pp. 621-622, (1952)
[6]  
Feinstein D.I., Rapaport S.I., Acquired inhibitors of blood coagulation, Prog Hemost Thromb, 1, pp. 75-95, (1972)
[7]  
Bowie W.E.J., Thompson J.H., Pascuzzi C.A., Owen C.A., Thrombosis in systemic lupus erythematosus, J Clin Invest, 62, pp. 416-430, (1963)
[8]  
Lechner K., A new type of coagulation inhibitor, Thromb Diath Haemorrh, 21, pp. 482-499, (1969)
[9]  
Schleider M.A., Nachman R.L., Jaffe E.A., Coleman M., A clinical study of the lupus anticoagulant, Blood, 48, pp. 499-509, (1976)
[10]  
Johanssen E.A., Lassus A., The occurrence of circulating anticoagulants in patients with syphilis and biologic false positive antilipoidal antibodies, Blood, 6, pp. 105-108, (1955)